InMed Pharmaceuticals Inc. has officially completed its merger with Mentari Therapeutics, Inc., a move that signifies a major transformation for the company. The merger, finalized on November 6, 2026, comes as part of a strategic plan to enhance operational capabilities and market presence in the pharmaceutical preparations industry.
The merger was executed under an Agreement and Plan of Merger and Reorganization, initially announced in May 2026. This agreement was amended in July 2026 to accommodate changes in the terms of the merger. With this merger, InMed has also undergone a significant rebranding, changing its name to Mentari Therapeutics.
Background
InMed Pharmaceuticals Inc., classified under the SIC code 2834 for Pharmaceutical Preparations, has been publicly traded on the Nasdaq under the tickers MTRI and INM. The company has been focused on developing innovative therapies for various medical conditions. Recent filings indicate that InMed has been actively pursuing growth strategies, including potential mergers and acquisitions, to bolster its position in the competitive pharmaceutical landscape.
What the Filing Says
The recent SEC filing details the completion of the merger, stating, "On November 6, 2026, Mentari Therapeutics, Inc. consummated the previously announced business combination." This merger involved a consolidation of InMed's outstanding shares and a change in its corporate structure, including a redomestication from British Columbia to Nevada. The filing also outlines the terms of the merger, including the conversion of shares and options from both companies into the new corporate structure.
Impact
This merger is expected to have significant implications for both InMed's existing shareholders and the broader pharmaceutical market. Following the merger, InMed shareholders will own approximately 1% of the newly formed company, while Mentari shareholders will control about 99%. This shift in ownership reflects the substantial influence of Mentari in the combined entity and highlights the trend of consolidation in the pharmaceutical industry.
What's Next
Moving forward, the company will likely focus on integrating operations and leveraging the combined resources to enhance product development and market reach. The filing does not specify any immediate next steps, but it is expected that further updates will be provided as the integration process unfolds.
This merger illustrates the ongoing evolution within the pharmaceutical preparations sector, where companies are increasingly looking to combine resources and expertise to navigate a competitive landscape. As InMed transitions to Mentari Therapeutics, it will be crucial to monitor how this change affects its strategic direction and market performance.
Read Next
Madison Technologies reports Q3 results with net loss
Cyberloq Technologies Releases Q3 Results Amid Challenges
Specificity, Inc. Reports Q3 2026 Financial Results
SUNation Energy reports Q3 2026 financial results
Vystar Corp reports on Q3 performance in latest filing
Alpex Acquisition Corp Reports Quarterly Results










